[HTML][HTML] Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study.
O Aljuhani, K Al Sulaiman, A Alshabasy… - BMC Infectious …, 2021 - go.gale.com
Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
O Aljuhani, K Al Sulaiman… - BMC infectious …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study.
O Aljuhani, K Al Sulaiman, A Alshabasy… - BMC Infectious …, 2021 - europepmc.org
Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
[HTML][HTML] Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
O Aljuhani, K Al Sulaiman… - BMC Infectious …, 2021 - bmcinfectdis.biomedcentral.com
Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly
inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and …
inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and …
[PDF][PDF] Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
O Aljuhani, K Al Sulaiman, A Alshabasy, K Eljaaly… - 2021 - scienceopen.com
Abstract Background: Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
O Aljuhani, K Al Sulaiman, A Alshabasy, K Eljaaly… - 2021 - repository.arizona.edu
Background: Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody
that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its …
that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its …
[HTML][HTML] Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
O Aljuhani, K Al Sulaiman, A Alshabasy… - BMC Infectious …, 2021 - ncbi.nlm.nih.gov
Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety …
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: a multicenter, retrospective cohort study.
O Aljuhani, K Al-Sulaiman, A Alshabasy, K Eljaaly… - 2021 - cabidigitallibrary.org
Abstract Background: Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
O Aljuhani, K Al Sulaiman, A Alshabasy… - BMC Infectious …, 2021 - ksascholar.dri.sa
Background: Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody
that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its …
that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its …